Technical Analysis for TCON - TRACON Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 1.55 4.03% 0.06
TCON closed up 4.03 percent on Tuesday, March 19, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical TCON trend table...

Date Alert Name Type % Chg
Mar 19 Upper Bollinger Band Walk Strength 0.00%
Mar 19 Inside Day Range Contraction 0.00%
Mar 19 Wide Bands Range Expansion 0.00%
Mar 19 Up 3 Days in a Row Strength 0.00%
Mar 19 Upper Bollinger Band Touch Strength 0.00%
Mar 18 Pocket Pivot Bullish Swing Setup 4.03%
Mar 18 Volume Surge Other 4.03%
Mar 18 Wide Bands Range Expansion 4.03%
Mar 18 Upper Bollinger Band Touch Strength 4.03%
Mar 15 NR7 Range Contraction 10.71%

Older signals for TCON ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration, and fibrotic diseases. Its lead product candidate is TRC105, which is in Phase II clinical trials for oncology indications, including soft tissue sarcoma, renal cell carcinoma, glioblastoma, and hepatocellular carcinoma. The company is planning for clinical trials of TRC105, including a Phase II clinical trial in patients with breast cancer and hepatocellular carcinoma, a Phase I clinical trial in patients with colorectal cancer, and a Phase I clinical trial in patients with lung cancer, as well as conducting preclinical studies of TRC105 in AMD. In addition, the company product candidates comprise TRC205, an anti-endoglin antibody that is in preclinical stage for the treatment of fibrotic diseases; and TRC102, a small molecule, which is in clinical development for the treatment of lung cancer and glioblastoma. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
Medicine Health Biopharmaceutical Cancer Drugs Clinical Trial Breast Cancer Colorectal Cancer Glioblastoma Targeted Therapy Age Related Macular Degeneration Hepatocellular Carcinoma Lung Cancer Renal Cell Carcinoma Therapeutics For Cancer Fibrotic Diseases Ros1 Transgene Sa
Is TCON a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 3.2
52 Week Low 0.5
Average Volume 465,129
200-Day Moving Average 1.7162
50-Day Moving Average 1.0525
20-Day Moving Average 1.2385
10-Day Moving Average 1.365
Average True Range 0.1561
ADX 45.08
+DI 33.8353
-DI 7.9324
Chandelier Exit (Long, 3 ATRs ) 1.2117
Chandelier Exit (Short, 3 ATRs ) 1.4082999999999999
Upper Bollinger Band 1.5703
Lower Bollinger Band 0.9067
Percent B (%b) 0.97
BandWidth 53.580945
MACD Line 0.1214
MACD Signal Line 0.098
MACD Histogram 0.0234
Fundamentals Value
Market Cap 25.82 Million
Num Shares 16.7 Million
EPS -1.75
Price-to-Earnings (P/E) Ratio -0.89
Price-to-Sales 17.03
Price-to-Book 2.65
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.75
Resistance 3 (R3) 1.74 1.67 1.71
Resistance 2 (R2) 1.67 1.62 1.67 1.70
Resistance 1 (R1) 1.61 1.59 1.64 1.62 1.69
Pivot Point 1.54 1.54 1.56 1.54 1.54
Support 1 (S1) 1.48 1.49 1.51 1.49 1.41
Support 2 (S2) 1.41 1.46 1.41 1.40
Support 3 (S3) 1.35 1.41 1.39
Support 4 (S4) 1.36